Show simple item record

dc.contributor.authorRuiz-Burga, Elisa
dc.contributor.authorTariq, Shema
dc.contributor.authorTouloumi, Giota
dc.contributor.authorGill, John
dc.contributor.authorNicholls, Emily Jay
dc.contributor.authorSabin, Caroline
dc.contributor.authorMussini, Cristina
dc.contributor.authorMeyer, Laurence
dc.contributor.authorVolny Anne, Alain
dc.contributor.authorCarlander, Christina
dc.contributor.authorGrabar, Sophie
dc.contributor.authorJarrin-Vera, Inmaculada 
dc.contributor.authorVan der Valk, Marc
dc.contributor.authorWittkop, Linda
dc.contributor.authorSpire, Bruno
dc.contributor.authorPantazis, Nikos
dc.contributor.authorBurns, Fiona M
dc.contributor.authorPorter, Kholoud
dc.contributor.authorCASCADE Collaboration
dc.date.accessioned2023-09-20T13:23:41Z
dc.date.available2023-09-20T13:23:41Z
dc.date.issued2023-05-11
dc.identifier.citationBMJ Open. 2023 May 11;13(5):e070837.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/16480
dc.description.abstractIntroduction: Despite the availability of pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART), 21 793 people were newly diagnosed with HIV in Europe in 2019. The Concerted action on seroconversion to AIDS and death in Europe study aims to understand current drivers of the HIV epidemic; factors associated with access to, and uptake of prevention methods and ART initiation; and the experiences, needs and outcomes of people with recently acquired HIV. Methods and analysis: This longitudinal observational study is recruiting participants aged ≥16 years with documented laboratory evidence of HIV seroconversion from clinics in Canada and six European countries. We will analyse data from medical records, self-administered questionnaires, semistructured interviews and participatory photography. We will assess temporal trends in transmitted drug resistance and viral subtype and examine outcomes following early ART initiation. We will investigate patient-reported outcomes, well-being, and experiences of, knowledge of, and attitudes to HIV preventions, including PrEP. We will analyse qualitative data thematically and triangulate quantitative and qualitative findings. As patient public involvement is central to this work, we have convened a community advisory board (CAB) comprising people living with HIV. Ethics and dissemination: All respective research ethics committees have approval for data to contribute to international collaborations. Written informed consent is required to take part. A dissemination strategy will be developed in collaboration with CAB and the scientific committee. It will include peer-reviewed publications, conference presentations and accessible summaries of findings on the study's website, social media and via community organisations.es_ES
dc.description.sponsorshipThis research is funded by ViiV Healthcare UK (award/grant number N/A), Janssen Pharmaceutica NV (award/grant number N/A) and Merck Sharp & Dohme (award/grant number N/A).es_ES
dc.language.isoenges_ES
dc.publisherBMJ Publishing Group es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subject.meshHIV Infections es_ES
dc.subject.meshAcquired Immunodeficiency Syndrome es_ES
dc.subject.meshPre-Exposure Prophylaxis es_ES
dc.subject.meshHumans es_ES
dc.subject.meshCanada es_ES
dc.subject.meshEurope es_ES
dc.subject.meshPatient Reported Outcome Measures es_ES
dc.subject.meshObservational Studies as Topic es_ES
dc.subject.meshMulticenter Studies as Topic es_ES
dc.titleCASCADE protocol: exploring current viral and host characteristics, measuring clinical and patient-reported outcomes, and understanding the lived experiences and needs of individuals with recently acquired HIV infection through a multicentre mixed-methods observational study in Europe and Canadaes_ES
dc.typeresearch articlees_ES
dc.rights.licenseAtribución-NoComercial 4.0 Internacional*
dc.identifier.pubmedID37169505es_ES
dc.format.volume13es_ES
dc.format.number5es_ES
dc.format.pagee070837es_ES
dc.identifier.doi10.1136/bmjopen-2022-070837es_ES
dc.contributor.funderViiV Healthcare (United Kingdom)es_ES
dc.contributor.funderJanssen Cilag es_ES
dc.contributor.funderMerck, Sharp & Dohme es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn2044-6055es_ES
dc.relation.publisherversionhttps://doi.org/10.1136/bmjopen-2022-070837es_ES
dc.identifier.journalBMJ openes_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES


Files in this item

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial 4.0 Internacional
This item is licensed under a: Atribución-NoComercial 4.0 Internacional